Biotech News
Related news
REPLReplimune Group2026-10-28 11:00 EST
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
REPLReplimune Group2026-10-22 12:00 EST
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
PRLDPrelude Therapeutics2026-11-16 12:01 EST
Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
MGNXMacroGenics2026-11-12 21:01 EST
MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
BMEABiomea Fusion2026-11-10 21:05 EST
Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
ZNTLZentalis2026-11-09 21:05 EST
Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
FATEFate Therapeutics2026-11-05 12:00 EST
Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
LYELLyell Immunopharma2026-11-04 21:05 EST
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
RVMDRevolution Medicines2026-11-04 21:02 EST
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
RLAYRelay Therapeutics2026-10-28 20:12 EST
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
NextCure
Oncology Drug Development NextCure develops novel therapies for cancer, with a pipeline that includes antibody-drug conjugates and immune-modulating approaches. SIM0505 SIM0505 is an antibody-drug conjugate targeting cadherin-6 and carrying a topoisomerase-1 inhibitor payload. It is being evaluated in tumors with elevated CDH6...
Recent company news
NXTCNextCure2026-08-06 20:01 EST
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
NXTCNextCure2026-07-14 10:00 EST
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
NXTCNextCure2026-06-04 12:00 EST
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
NXTCNextCure2026-06-01 12:00 EST
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
NXTCNextCure2026-05-07 20:05 EST
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
Stock data
- Close
- 6.78 USD
- Market cap
- 12.28M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
